Get the Stockscreener App
9.06
1.57%
0.14
Tyra Biosciences Inc stock is traded at $9.06, with a volume of 205.10K.
It is up +1.57% in the last 24 hours and down -15.25% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$8.92
Open:
$8.73
24h Volume:
205.10K
Relative Volume:
0.68
Market Cap:
$447.55M
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-5.6273
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
+7.47%
1M Performance:
-15.25%
6M Performance:
-68.06%
1Y Performance:
-39.52%
1-Day Range:
$7.80
$9.11
1-Week Range:
$7.80
$9.11
52-Week Range:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
9.06 | 447.55M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Average PT from Brokerages - Defense World
(TYRA) Investment Analysis and Advice - news.stocktradersdaily.com
Vanguard Group Inc. Sells 37,643 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Wellington Management Group LLP Has $1.32 Million Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
American Century Companies Inc. Sells 20,857 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
KLP Kapitalforvaltning AS Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm! - ACCESS Newswire
Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Raymond James Financial Inc. Invests $761,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
HC Wainwright Predicts Reduced Earnings for Tyra Biosciences - Defense World
Tyra Biosciences stock hits 52-week low at $8.14 - Investing.com Australia
Tyra Biosciences stock hits 52-week low at $8.14 By Investing.com - Investing.com South Africa
(TYRA) Technical Data - news.stocktradersdaily.com
Tyra Biosciences (NASDAQ:TYRA) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $30 target on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Swiss National Bank - Defense World
What is Wedbush’s Estimate for TYRA FY2029 Earnings? - Defense World
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Citizen Tribune
Wedbush Reiterates “Outperform” Rating for Tyra Biosciences (NASDAQ:TYRA) - Defense World
Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth - Yahoo Finance
Charles Schwab Investment Management Inc. Trims Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Tyra Biosciences Advances Precision Medicine Pipeline - TipRanks
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Bought by Bank of New York Mellon Corp - Defense World
Tyra Biosciences stock hits 52-week low at $9.9 amid market challenges By Investing.com - Investing.com South Africa
Tyra Biosciences stock hits 52-week low at $9.9 amid market challenges - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus Target Price from Analysts - Defense World
Trend Tracker for (TYRA) - news.stocktradersdaily.com
Victory Capital Management Inc. Purchases 26,560 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthc - GuruFocus.com
US Bancorp DE Purchases Shares of 3,612 Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Tyra Biosciences (NASDAQ:TYRA) Sees Large Volume Increase – Should You Buy? - Defense World
Tyra Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
(TYRA) On The My Stocks Page - Stock Traders Daily
Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges - Investing.com Australia
Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges By Investing.com - Investing.com South Africa
Rhumbline Advisers Grows Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Large Growth in Short Interest - Defense World
Advanced Urothelial Carcinoma Clinical Trial Pipeline - GlobeNewswire
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Non-Muscle Invasive Bladder Cancer Clinical and Non-Clinical - openPR
(TYRA) Investment Report - Stock Traders Daily
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):